|
Hi, Lynne. My ratio is 10.5. I've been wondering about this, also. I'll be watching this thread. Good question! And welcome to the HER2 board!
If I'm reading it right, it says that the ratio is meaningless as far as prognostic value goes.
If you google "FISH ratio" and "medscape", you'll find the article and won't need to log in.
Here are the first 2 paragraphs:
January 14, 2008 (San Antonio) — Data from the largest human epidermal growth-factor-receptor-2-positive breast cancer adjuvant trial show no prognostic value of central fluorescence in situ hydridization (FISH). Presenting at the recent 30th Annual San Antonio Breast Cancer Symposium, Worta McCaskill-Stevens, MD, from the National Cancer Institute in Bethesda, Maryland, reported a benefit in disease-free survival in a cohort of patients who were not FISH positive, but who were centrally confirmed for immunohistochemistry 3 and HER2 positivity.
The researchers found that this was also the case for FISH-positive patients with lower HER2 expression (immunohistochemistry 2+). And they observed no significant interaction between HER2 gene-copy number and the relative disease-free survival benefit of trastuzumab (Herceptin, Genentech and Roche).
__________________
IDC Stage IIIA
Diagnosed Nov 2006 (routine mammogram), age 51
Lumpectomy, lymph node dissection Dec 2006
3 cm tumor, 8 cancerous lymph nodes
Grade 3, ER/PR -, HER-2/neu +++ (by FISH, average 20 copies per cell)
A/C x 4, Taxol x 12, Herceptin x 47 weeks
35 radiation treatments
Completed treatment on April 3, 2008
Chest port removed October 2009
11 years since diagnosis NED
|
Linear Mode
